Clene Nanomedicine, Inc
6550 S. Millrock Dr.
Salt Lake City
About Clene Nanomedicine, Inc
Clene is transforming medicine through the application of physics and material science to resolve cellular bioenergetic failure. Our objective is not only to treat patients with neurodegenerative disease but to empower them by harnessing the power of nanocrystalline catalysts to reverse degenerative mechanisms. Clene is rapidly advancing a pipeline of bioenergetic nanotherapeutics designed to enhance naturally occurring cellular metabolism with the goal of reversing neurodegeneration.
Stock Symbol: CLNN
7 articles with Clene Nanomedicine, Inc
Clene Inc. and its wholly owned subsidiary Clene Nanomedicine, Inc., announced that it has been added as a member of the U.S. small-cap Russell 2000® Index and the all-cap Russell 3000® Index, effective after the U.S. market opens today, June 28, 2021, as part of the 2021 Russell indexes reconstitution.
Clene Inc. and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company dedicated to the treatment of neurodegenerative disease using bioenergetic nanocatalysis, announced that Rob Etherington, President and Chief Executive Officer, will present at the Raymond James Human Health Innovation Conference on Tuesday, June 22, 2021 at 11:20 a.m. ET.
Clene Inc. (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company dedicated to the treatment of neurodegenerative disease using bioenergetic nanocatalysis, today announced the appointment of David J. Matlin as Chairman of the Board.
Clene Nanomedicine Receives Catalyst Award for Healthy Longevity from U.S. National Academy of Medicine to Accelerate the Development of CNM-Au8 for Neurodegenerative Diseases Associated with Aging
International award will fund preclinical study of CNM-Au8 nanocatalysis for the improvement of human health and lifespan in the contexts of aging and Alzheimer’s disease
A platform trial is also efficient in that it enables the investigators to share placebo information.
Interim Phase 2 data indicate that CNM-Au8 has a homeostatic effect on brain bioenergetics and support its potential to drive meaningful neurological functional improvements in MS patients
Clene Inc. and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company dedicated to revolutionizing the treatment of neurodegenerative disease using nanocatalysis, reported its full year 2020 operating and financial results.